The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in merkel cell carcinoma patients with clinically detected lymph node metastases; NCT03271372.
 
Shailender Bhatia
Honoraria - EMD Serono; Genentech/Roche
Consulting or Advisory Role - EMD Serono; Genentech/Roche
Research Funding - Bristol-Myers Squibb (Inst); Conkwest (Inst); EMD Serono (Inst); Immune Design (Inst); Merck (Inst); NantWorks (Inst); OncoSec (Inst)
Travel, Accommodations, Expenses - EMD Serono; NantWorks
 
Andrew Scott Brohl
Expert Testimony - GlaxoSmithKline (I)
 
Isaac Brownell
No Relationships to Disclose
 
Sunandana Chandra
Consulting or Advisory Role - Biodesix; Bristol-Myers Squibb; EMD Serono; Regeneron
Research Funding - Bristol-Myers Squibb (Inst)
Other Relationship - Biodesix; Bristol-Myers Squibb; EMD Serono; Regeneron
 
Sumia Dakhil
No Relationships to Disclose
 
Marc S. Ernstoff
Stock and Other Ownership Interests - GE Healthcare
Consulting or Advisory Role - Bristol-Myers Squibb; Celyad; EMD Serono; Lion Biotechnologies; Omniseq
Research Funding - Alkermes (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Merrimack (Inst)
 
Leslie Anne Fecher
Consulting or Advisory Role - Via Oncology
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst)
Other Relationship - AIM at Melanoma Foundation; Hoosier Cancer Research Network
 
Ted Gooley
No Relationships to Disclose
 
Glenn J. Hanna
Research Funding - Bristol-Myers Squibb (Inst)
 
Reina Hibbert
Travel, Accommodations, Expenses - Five Prime Therapeutics; Nektar
 
Ciara Marie Kelly
No Relationships to Disclose
 
Samantha M. Kiriluk
No Relationships to Disclose
 
Paul Nghiem
Honoraria - EMD Serono; Merck Sharp & Dohme
Consulting or Advisory Role - EMD Serono; Pfizer
Research Funding - Bristol-Myers Squibb; EMD Serono
Patents, Royalties, Other Intellectual Property - Patent pending for high affinity T cell receptors that target the Merkel polyomavirus.
 
Vivian Nguyen
No Relationships to Disclose
 
Nichole Pelz
Travel, Accommodations, Expenses - EMD Serono
 
Aubrey A. Poisson
No Relationships to Disclose
 
Katharine Andress Rowe Price
No Relationships to Disclose
 
Vernon K. Sondak
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck/Schering Plough; Novartis; Provectus
 
John A. Thompson
Consulting or Advisory Role - Boehringer Ingelheim; Calithera Biosciences; Celldex; Nektar; Seagen
Research Funding - Agensys (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst); Trillium Therapeutics (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Scott S. Tykodi
Consulting or Advisory Role - Bristol-Myers Squibb; Calithera Biosciences
Research Funding - Argos Therapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Jounce Therapeutics (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst)